Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma

BackgroundThe prognostic significance of oestrogen and progesterone receptors (ER/PR) in endometrial stromal sarcoma (ESS) has conflicting reports in the literature, and the routine use of adjuvant progestogen is of uncertain efficacy. AimsTo examine the prognostic significance of ER/PR positivity and of primary adjuvant progestogen use with outcome in ESS. Materials and MethodsAll women with a diagnosis of ESS in our tertiary institution and associated private practices over the last 23years were included. Primary variables were ER/PR positivity and adjuvant progestogen use. Other variables included high-grade disease and extrauterine disease. The primary outcome was survival, and the secondary outcome was recurrence-free survival (both overall and at 5years). Survival was calculated using the Kaplan-Meier method. Univariate analyses were performed with t-test for means and chi-squared test for proportions, and multivariate analysis was used to control for age. Results35 women were included. ER/PR positivity was associated with a survival benefit (OR death 0.22, P=0.02), but primary adjuvant progestogen was not. High-grade disease (OR 13, P=0.02) and extrauterine disease (OR 8.7, P=0.04) were associated with decreased survival. No variable significantly affected recurrence-free survival. Eight of ten cases of recurrence treated with progestogen have survived more than 3years. ConclusionsER/PR positivity appears to be useful for prognosis, but routine administration of primary adjuvant progestogen is not supported. There may be a role for progestogen in ER/PR positive tumours with recurrence or incomplete surgical clearance, but further research is required.